Cudnik, Ryan J.

For complex and high-profile patent and IP actions, such as Hatch-Waxman (ANDA) litigations, numerous Fortune 500 companies have trusted Ryan with their cases. Ryan has litigated a broad range of intellectual property (IP) cases, including litigations over “blockbuster” pharmaceutical products with global sales exceeding $1 billion per year and bet-the-company gaming litigations involving a blend of IP and contract issues. His complex patent litigation experience includes multidistrict litigations (MDL), Hatch-Waxman (ANDA) litigations, and unfair import investigations (section 337 patent infringement actions) in the U.S. International Trade Commission. Ryan has also handled high-stakes trademark and trade secret litigation.

Prior to joining the firm, Ryan practiced intellectual property law at Watson Rounds, a firm Brownstein merged with September 1, 2015, Finnegan Henderson in Washington, D.C., and Fitzpatrick Cella in New York, NY. Prior to law school, he worked as a high school teacher and varsity lacrosse and soccer coach.

Representative Matters
  • Represented NewDay Financial in a declaratory judgment action against United Services Automobile Association (“USAA”) in the District of Maryland involving USAA’s allegations of copyright and trademark infringement.  A motion to dismiss USAA’s first-filed complaint in the Northern District of Texas was granted for lack of personal jurisdiction. Case settled

  • Represented Galaxy Gaming in an AAA arbitration proceeding regarding Galaxy’s table game High Card Flush. Prevailed on issues of intellectual property ownership, willful infringement, fraud, permanent injunction, and attorneys’ fees.

  • Aervoe Indus., Inc. v. PMG, Inc., No. 3:14-cv-00488 (D. Nev. 2014) (declaratory judgment action for patent noninfringement and patent invalidity).

  • Walker Digital Table Systems, LLC v. GPI Corp., No. 2:14-cv-00438 (D. Nev. 2014) (patent litigation regarding phase jitter modulation RFID technology).

  • Counseled Walker Digital Table Systems, LLC regarding various business and patent licensing issues.

  • In the Matter of Certain Gemcitabine and Products Containing the Same, Inv. No. 337-TA-766 (U.S. ITC) (unfair import investigation).

  • Eli Lilly and Co. v. Sicor Pharm., Inc., 705 F. Supp. 2d 971 (S.D. Ind. 2010) (ANDA litigation regarding Gemzar®).

  • Adams Respiratory Therapeutics, Inc. v. Pharmaceutical Holdings Corp., No. 06-cv-4418 (E.D. Pa.) (ANDA litigation regarding Mucinex®).

  • Astellas Pharma, Inc. v. Ranbaxy, Inc., No. 05-cv-2563, 2007 WL 576341 (D.N.J. Feb. 21, 2007) (ANDA litigation regarding Flomax®).

  • Merck and Co. v. Dr. Reddy’s Lab. Ltd., No. 04-cv-1313 (D. Del.) (ANDA litigation regarding Propecia®).

  • In re Omeprazole Patent Litigation, MDL Docket No. 1291, Master Docket No. M-21-81 (S.D.N.Y.) (ANDA litigation regarding Prilosec®).

  • In re Gabapentin Patent Litigation, MDL Docket No. 1384, Master Docket No. 00-cv-2931 (D.N.J.) (ANDA litigation regarding Neurontin®).

News & Events
Publications & Presentations
  • J.D., 2002, Catholic University of America, Columbus School of Law
  • B.S., Biology, 1996, Hampden-Sydney College
  • Nevada
  • New York
  • Maryland
  • District of Columbia
  • U.S. District Court, District of Nevada
  • U.S. District Court, Southern District of New York
  • U.S. District Court, Eastern District of New York
  • U.S. Court of Appeals, Federal Circuit

American Bar Association

American Intellectual Property Association